AMENDMENTS TO THE CLAIMS

This listing replaces all prior versions and listings of claims in the application:

Listing of Claims

1. (Currently amended) A method of qualifying ~~ischaemic heart disease status~~ the severity of myocardial infarction in a subject who has suffered a myocardial infarction, comprising:

(a) measuring ~~at least one biomarker~~ in a sample from the subject the amount ~~,~~ ~~wherein the biomarker is selected from the group consisting~~ of biomarkers galectin-3 and fibrinogen ~~galectin-3 fragments~~, and

(b) correlating the measurement with ~~ischaemic heart disease status~~ either severe myocardial infarction or mild myocardial infarction.

2. (Currently amended) The method of claim 1, further comprising:

(c) managing subject treatment based on the ~~status~~ severity of myocardial infarction.

3. (Currently amended) The method of claim 2, wherein managing subject treatment is selected from ordering more tests, performing surgery, prescribing medication, ~~and~~ or taking no further action.

4. (Currently amended) The method of claim 2, further comprising:

(d) measuring at least one of said biomarkers ~~biomarker~~ after subject management.

Claims 5 to 6 (Cancelled)

7. (Currently amended) The method of claim 1, wherein measuring comprises:

(a)   providing a subject sample of blood or a blood derivative;

(b)   fractionating proteins in the sample and collecting fractions that contain galectin-3 and fibrinogen biomarkers ~~or a galectin-3 fragment biomarker~~; and

-2-

(c)   capturing the biomarkers from the fractions on a surface of a substrate comprising capture reagents that bind the biomarkers.

8. (Currently amended) The method of claim 7, wherein the substrate is a SELDI probe comprising an adsorbent that captures the biomarkers and wherein the biomarkers are ~~detected~~ measured by SELDI.

9. (Original) The method of claim 8, wherein the SELDI probe comprises a biospecific affinity reagent that binds the biomarkers.

10. (Currently amended) The method of claim 7, wherein the substrate is a microtiter plate comprising biospecific affinity reagents that bind the biomarkers and the biomarkers are ~~detected~~ measured by immunoassay.

11. (Cancelled)

12. (Currently amended) The method of claim 1, wherein at least one biomarker is measured ~~using~~ with a biochip array.

13. (Original) The method of claim 12, wherein the biochip array is a protein chip array.

14. (Original) The method of claim 12, wherein at least one biomarker is immobilized on the biochip array.

15. (Original) The method of claim 1, wherein the biomarkers are measured by SELDI.

16. (Original) The method of claim 1, wherein the biomarkers are measured by immunoassay.

17. (Original) The method of claim 1, wherein the correlating is performed by a software classification algorithm.

18. (Currently amended) The method of claim 1, wherein the sample is selected from blood, serum ~~and~~ or plasma.

Claims 19 to 56 (Cancelled)